Navigate Fool.com
Will THLD beat
the market?
Community Rating: 4 Stars: Favorite

4.21 0.07 (1.69%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.17
Previous Close $4.14
Daily Range $4.14 - $4.27
52-Week Range $3.51 - $5.93
Market Cap $249.8M
P/E Ratio -8.81
Dividend (Yield) $0.00 (0.0%)
Volume 301,383
Average Daily Volume 390,075
Current FY EPS -$0.51

How do you think THLD
will perform against the market?

Top THLD Bull/Bear Pitches


zzlangerhans (< 20)
Submitted October 10, 2012

Threshold is a great example of how I now use CAPS as a map for future trades. Right now, the stock is clearly in decline due to a crisis in confidence about the clinical and commercial potential of h … More

5 Replies Reply Report this Post

pavlos1971 (< 20)
Submitted March 26, 2013

I plan to hold this caps pick through the clinical trials. Br vs Cl in a clinical compound matters, but probably not as much when you have reactive or otherwise ugly-looking chemistry, so I expect th … More

0 Replies Reply Report this Post

News & Commentary

3 Stocks Near 52-Week Lows Worth Buying

Do Westport Innovations, Threshold Pharmaceuticals, and and Rowan Cos. deserve a second chance? You be the judge!

Sector Update: Healthcare Shares Mixed Pre-Market; Pfizer Sinks 3% on Results of Breast Cancer Treat

Sector Update: Healthcare Shares Mixed Pre-Market; Pfizer Sinks 3% on Results of Breast Cancer Treatment Study

Sector Update: Healthcare Shares Edging Higher in Pre-Bell Trade

Sector Update: Healthcare

5 States Where Pancreatic Cancer Prevalence Is the Highest

Pancreatic cancer has the lowest five-year survival rate and is the most prevalent in these five states. Here are the existing and developing therapies you need to have your eyes on.

3 Biotech Companies That Could Be the Next Intercept or InterMune

With Intercept and InterMune stocks jumping 525% and 171%, respectively, biotech-savvy investors are eagerly looking for the next big thing. It just might be one of these three companies.

How Researchers Are Waging War on the Most Lethal Type of Cancer

Pancreatic cancer is the 12th most diagnosed cancer, but it is by far the most lethal. Find out how treatments are evolving and how patients and investors may soon benefit from these discoveries.

3 Stocks to Get on Your Watchlist

A revolutionary cancer-fighting biotech, an incredibly inexpensive oil refiner, and an iconic newspaper company are this week's must-watch stocks.

This Biotech Has So Many Reasons to Be Liked

Incyte has other good stories besides Jakafi indicated for myelofibrosis.

Incyte Jumps on Jakafi Results

Shares up big for this biotech on great news from a phase 2 pancreatic cancer study.

See More THLD News...






A biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer. Website: http://www.thresholdpharm.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks